Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 26 May, 2010

Lipoxen PLC

Vaccine Patent

RNS Number : 5318M
Lipoxen PLC
26 May 2010
 



FOR IMMEDIATE RELEASE

RNS Reach

26 May 2010

 

 

 

Lipoxen plc

('Lipoxen' or 'the Company')

Expansion of DNA Vaccine Patent Allowed in US

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that an expansion of its DNA Vaccine Patent ("Patent") has been allowed in the US for its ImuXen® liposomal gene technology.

The ImuXen® technology allows the liposomal entrapment of vaccine materials, resulting in enhanced immune responses which potentially could lead to single dose immunity being achieved while reducing the side effects associated with traditional vaccines. The new Patent protects the use of a range of additional cationic lipids that can form the building molecules of Lipoxen's ImuXen® liposomes.

This Patent expansion strengthens and broadens Lipoxen's existing ImuXen® patents which protect the co-delivery DNA and antigen and delivery of antigen alone.

Commenting on these results, Scott Maguire, CEO said: "This Patent extension is important as it further protects the patent position of our gene vaccine technology.  Such added protection will provide value to commercial partners seeking long term exclusivity in the vaccine market."

For further information, please contact:

Enquiries 

Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång




Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen


 

About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:

 

1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

 

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 

 

Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for Factor VIII.

 

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010.

 

Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQELFLBEFLBBL